Ken Griffin Aim Immuno Tech Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 457,767 shares of AIM stock, worth $86,975. This represents 0.0% of its overall portfolio holdings.
Number of Shares
457,767
Previous 98,027
366.98%
Holding current value
$86,975
Previous $36,000
241.67%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$822,7000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$377,8530.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$132,6700.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$88,1630.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny243KShares$46,2090.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $9.13M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...